Genentech: Gina Xiaojing Wang | Senior Principal Scientist (Chemistry), Discovery Chemistry

Scientists / Our Scientists

"Helping patients is my mission and innovation is the strategy. Innovating for life is especially meaningful and gratifying."

Years at Genentech

Publications at Genentech

Awards & Honors

I decided to join Genentech at 2006 as a scientist. What appealed me particularly to work at Genentech was the casual yet intense science-driven culture. Over the years, I led multiple disciplinary teams in driving projects towards deliveries into our pipeline of experimental therapies. It has been so much fun doing science together with super talented colleagues from all levels.

Today, I am a Principal Scientist and Project Team Lead, mentoring junior scientists and leading teams in discovering therapeutics of novel targets. What we are working on is often very challenging but we are fully motivated by patients who are waiting for breakthrough medicines.

Featured Publication

From Discovery to Bedside: Targeting the Ubiquitin System.

Cell Chem Biol. 2018 Nov 28. pii: S2451-9456(18)30382-9.

Wertz IE, Wang X.

View Abstract

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton0s Tyrosine Kinase with Improved Druglike Properties.

ACS Med Chem Lett. 2017 May 3;8(6):608-613.

Wang X, Barbosa J, Blomgren P, Bremer MC, Chen J, Crawford JJ, Deng W, Dong L, Eigenbrot C, Gallion S, Hau J, Hu H, Johnson AR, Katewa A, Kropf JE, Lee SH, Liu L, Lubach JW, Macaluso J, Maciejewski P, Mitchell SA, Ortwine DF, DiPaolo J, Reif K, Scheerens H, Schmitt A, Wong H, Xiong JM, Xu J, Zhao Z, Zhou F, Currie KS, Young WB.

View Abstract

As a medicinal chemist, my focus is to invent novel therapeutic modalities for the treatment of various disease areas through hit identification and lead optimization integrating efficacy, pharmacokinetics and safety profile. The innovation includes new chemical matters and novel mode or mechanism of action. I am also interested in investigating tissue specific delivery to maximize safety margin of effective therapies.

Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer

Bioorganic and Medicinal Chemistry Letters, ISSN: 14643405 0960894X

Jason R. Zbieg; Jun Liang; Jun Li; Robert A. Blake; Jae Chang; Lori S. Friedman; Simon Goodacre; Steven J. Hartman; Ellen Rei Ingalla; James R. Kiefer; Tracy L. Kleinheinz; Sharada Labadie; Tommy Lai; Jiangpeng Liao; Neville J. McLean; Ciara Metcalfe; Vidhi Mody; Michelle Nannini; Daniel F. Ortwine; Yingqing Ran; Nicholas C. Ray; Fabien Roussel; Amy Sambrone; Deepak Sampath; Maia Vinogradova; John Wai; Tao Wang; Kuen Yeap; Birong Zhang; Xiaoping Zheng; Yu Zhong; Xiaojing Wang

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Gina Xiaojing Wang

Senior Principal Scientist (Chemistry), Discovery Chemistry

Featured Publication

From Discovery to Bedside: Targeting the Ubiquitin System.

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton0s Tyrosine Kinase with Improved Druglike Properties.